MAPT and early-onset autosomal dominant Alzheimer disease: The now-standard biomarker model of Alzheimer’s disease, proposed by Jack et al. (2013), notes that structural MRI is typically one of the last biomarkers to show detectable changes - after CSF Abeta42, Amyloid PET, and CSF Tau.